A Study to Test How Well Empagliflozin Works in Chinese Patients With Type 2 Diabetes Who Already Take Insulin
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 219 participants.
Also called NCT04233801
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 219 participants
- Sponsor
- Registry
-
NCT04233801
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT04233801. Randomized; triple masking; primary purpose treatment. Start 2020-04-15 (actual); primary completion 2022-03-03 (actual). Results posted on 2023-12-15.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Test How Well Empagliflozin Works in Chinese Patients With Type 2 Diabetes Who Already Take Insulin
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Empagliflozin
- Intervention (Drug)
- Placebo
- Lead sponsor
- Boehringer Ingelheim
Record details
- Record id
cardio:ct-nct04233801- Content hash
a2e7aa18d77fc9636b99f1ce0d314e8133c2858d228096fccc6e6febe79627df